Policy, funding, community, and developments from the wider world — reported plainly, with the journalism it's drawn from cited in full.
Autism services are undergoing significant policy changes across the U.S., with Minnesota implementing new licensing requirements for providers while North Carolina restricts out-of-state and telehealth options. Federal funding continues through the Autism CARES Act, but new Medicaid rules may create hurdles for autistic individuals and their families accessing services.
Recent regulatory and clinical trial activity highlights efforts to develop medications addressing specific challenges some autistic individuals face, though none modify core autistic traits. The FDA is reviewing leucovorin (folinic acid) for language support in autistic people with cerebral folate deficiency — a rare metabolic condition affecting folate transport to the brain. Other trials investigate vasopressin nasal spray and suramin, but current FDA-approved medications like risperidone only address co-occurring irritability. A 2026 systematic review found most preclinical drug candidates fail in human trials, underscoring the complexity of translating findings from animal models to autistic people.
The CDC's latest report finds 3.2% of U.S. 8-year-olds were identified as autistic in 2022, up from 2.8% in 2020. The increase reflects reduced disparities in diagnosis access, particularly for historically underserved groups, though boys remain 3.4 times more likely to be identified than girls.
Recent statements by political figures have brought attention back to long-disputed claims about autism's causes, despite clear scientific consensus. Researchers and autistic advocates are responding with evidence-based information, stressing the importance of focusing on support and inclusion rather than unsubstantiated causation theories.
The federal government has renewed major funding for autism programs through the Autism CARES Act, authorizing nearly $2 billion over five years for research and supports. Meanwhile, states like Minnesota and North Carolina are taking different approaches to regulating service providers, with potential implications for accessibility and quality of supports.
A growing number of autism organizations, researchers, and healthcare systems are recognizing the importance of autistic self-advocacy and neurodiversity principles in shaping research, policy, and care. However, tensions remain over how to best address the needs of autistic individuals with high support needs and those who are non-speaking.
Sector-specific training programs and virtual reality (VR) tools are being developed to support autistic adults in navigating workplace challenges, particularly in technical fields like semiconductors. While these initiatives highlight the value of accommodations such as VR simulations and mentorship, broader systemic barriers and funding gaps continue to leave many autistic job seekers without adequate support.
School districts are adding specialized supports for autistic students as diagnoses rise due to broader recognition, updated criteria, and potential increases in occurrence. Governments acknowledge systemic gaps, while research identifies school avoidance, educator attitudes, and lack of autistic input as barriers. Tailored strategies, training, and community collaboration emerge as key to meaningful inclusion.
The FDA has initiated approval for leucovorin calcium tablets to address cerebral folate deficiency (CFD) in autistic individuals - a metabolic difference where folate transport to the brain is reduced. While this marks progress in targeting specific biological pathways, the drug's off-label use for broader autism-related traits is increasing despite limited clinical evidence. Currently, only risperidone and aripiprazole are FDA-approved for autism-related distress responses, with no medications targeting core social and communication patterns. Research continues exploring repurposed drugs and new candidates, though translation from animal studies remains challenging.
The CDC's 2025 report reveals autism prevalence among 8-year-olds increased to 1 in 31 (3.2%) in 2022, up from 1 in 36 in 2020. This rise reflects improved screening and diagnosis, particularly for Black, Hispanic, and female children, with the male-to-female ratio decreasing from 4.2:1 to 3.8:1. Significant state-level variations persist, from 1 in 19 in California to 1 in 103 in Texas.
Long-disproven claims about autism origins have regained attention through political channels, prompting researchers to reassert decades of scientific evidence and launch independent initiatives to support accurate public understanding.
State approaches to autism services are diverging — with California preserving access and North Carolina limiting telehealth options — even as federal autism research funding reaches record levels under the reauthorized CARES Act. These disparities underscore how location affects service availability for autistic individuals, with some states implementing quality improvements while others adopt restrictions that may limit care options.
Autistic self-advocates are driving a paradigm shift in autism research and support, with major organizations affirming community-centered approaches and rejecting cure-focused agendas. Peer-reviewed studies and institutional statements highlight the gap between traditional clinical perspectives and autistic lived experience, while late-diagnosed individuals document transformative journeys from shame to advocacy.
Prescriptions of leucovorin for autistic children rose significantly after media coverage and policy announcements, despite the FDA clarifying it's not approved for autism treatment. This reflects families' search for pharmacological options, though experts note current medications only address co-occurring conditions, not core autism traits, and underscore the importance of behavioral therapies and accommodations.
Leading autism researchers have formed an independent committee to counter misinformation after the CDC altered its autism-vaccine information to include debunked claims. Multiple large studies confirm no evidence linking Tylenol use during pregnancy to autism, while decades of research disprove vaccine-autism links. Meanwhile, core psychological theories about autism face evidence-based challenges in the scientific community.
The Autism CARES Act has been renewed with $1.95 billion in funding for research and services, as states like North Carolina and Minnesota introduce new regulations affecting provider oversight and telehealth access.
A growing consensus among researchers and advocacy groups emphasizes the need to center autistic lived experience in autism research and support. Joint statements, academic studies, and institutional initiatives highlight the importance of rejecting stigma, recognizing autistic burnout, and prioritizing accommodations over curative approaches. However, challenges remain in diagnostic practices, representation authenticity, and power-sharing with historically marginalized subgroups.
The largest clinical trial on leucovorin (folinic acid) for autism was retracted in February 2026 due to implementation errors, raising questions about its evidence base. While prescriptions increased following policy changes, rigorous research remains limited. No medication currently targets autism's core characteristics, though some address co-occurring challenges.
The CDC's ADDM Network reports autism identification among US eight-year-olds reached 3.2% (1 in 31) in 2022, up from 2.8% in 2020. Researchers attribute this primarily to expanded screening and reduced diagnostic bias, though access gaps persist in some communities.
Political pressure has led to institutional shifts contradicting decades of autism research, including ambiguous CDC website changes regarding vaccines. Scientists have mobilized to reaffirm the lack of consistent evidence linking prenatal Tylenol use to autism, while clarifying that observed Theory of Mind differences in autism reflect diverse cognitive styles rather than deficits. The scientific community continues to counter misinformation by emphasizing evidence-based approaches and the importance of autistic voices in research.
Recent state-level policy changes and federal debates highlight tensions in autism support delivery, even as bipartisan support for research funding remains strong through the reauthorized Autism CARES Act.
Education systems in Ireland, Sweden, and Pennsylvania are piloting neurodiversity-informed supports, from Ireland's flexible ['inclusive special' classes](https://www.irishexaminer.com/opinion/commentanalysis/arid-41882131.html) to Sweden's teacher training reforms. However, a [2026 PMC meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC12618732/) of 42 studies cautions that success hinges on individualized adaptations and centering autistic voices—a practice still rare in policy design.
A 2026 retraction of a 120-participant leucovorin trial due to randomization flaws has tempered expectations about pharmacological approaches for autism-related support needs. While no FDA-approved drugs target social-communication differences, emerging research explores targeted approaches including [oxytocin modulation](https://www.nature.com/articles/s41380-026-03663-8) and [bumetanide trials](https://www.technologynetworks.com/drug-discovery/news/experimental-epilepsy-drug-shows-promise-for-autism-treatment-403661). The episode highlights the importance of participant stratification and neurodiversity-informed research design.
The CDC's Autism and Developmental Disabilities Monitoring (ADDM) Network estimates 1 in 31 8-year-olds in its surveillance sites were identified as autistic in 2022, up from 1 in 36 in 2020. The increase reflects long-standing improvements in diagnostic practices and broader recognition of neurodivergence, particularly among historically underdiagnosed groups. Regional and demographic variations persist, underscoring ongoing disparities in access to evaluation services.
The scientific community is responding to renewed misinformation campaigns about autism causes, including disproven links to vaccines and acetaminophen use during pregnancy. Following controversial CDC website edits in November 2025 that appeared to legitimize these claims, researchers formed the Independent Autism Coordinating Committee in March 2026 to provide accurate information about autism's neurodevelopmental origins. This effort reinforces decades of research showing no causal relationship between these factors and autism, while challenging outdated concepts about autistic cognition.
The Trump administration has renewed federal coordination on autism policy through new appointments to the Interagency Autism Coordinating Committee, while states like Minnesota investigate Medicaid billing practices. The Autism CARES Act reauthorization secured $1.95 billion in federal funding through 2029, but debates continue over research priorities and Medicaid oversight.
Growing interest in leucovorin calcium for cerebral folate deficiency has coincided with increased off-label prescribing for autism, as scientists investigate various approaches to support autistic individuals. While risperidone and aripiprazole remain the only FDA-approved medications for associated irritability, researchers are examining novel supports including vasopressin nasal sprays and repurposed medications in early-stage trials.
The CDC's 2022 autism surveillance data indicates 3.2% of eight-year-olds in monitored U.S. regions received autism diagnoses, up from 2.8% in 2020. Increased identification among Black, Hispanic, Asian/Pacific Islander children and girls suggests reduced disparities in diagnostic access, though geographic variations highlight ongoing service gaps. Scientists attribute the shift to expanded screening tools and awareness, not a true increase in autism occurrence.
A coalition of autism researchers and advocates has established an Independent Autism Coordinating Committee to counter misinformation promoted by political figures, including RFK Jr.'s advisory panel. This follows November 2025 CDC website edits that removed definitive language about vaccine safety without altering the underlying science. Multiple authoritative reviews confirm no causal link exists between vaccines and autism, while research on acetaminophen remains inconclusive but shows no clear causation. The 'mind blind' theory of autism has been widely challenged by contemporary research recognizing neurocognitive differences rather than deficits.
Recent policy changes at federal and state levels are expanding funding and services for autistic individuals, though debates persist over telehealth access and research priorities. Congress allocated nearly $400 million for autism programs in 2026, while states like Minnesota implemented new licensing requirements for providers. However, North Carolina's telehealth restrictions and HHS Secretary Kennedy's focus on autism causation research have drawn criticism.
Workforce programs are exploring ways to support autistic employment through STEM-focused training, virtual reality tools, and inclusive hiring models. While systemic barriers persist, structured adjustments and transition support show promise in creating more equitable opportunities.
The FDA has approved leucovorin calcium specifically for treating cerebral folate deficiency (CFD) in autistic individuals, a metabolic condition distinct from autism itself. While prescriptions have risen significantly, experts emphasize this does not indicate efficacy for core autistic traits and call for more rigorous trials.
The CDC's latest ADDM Network report finds autism identification among 8-year-olds rose to 1 in 31 (3.2%) in 2022, with significant geographic and demographic variations in identification patterns.
Recent political appointments and alterations to CDC communications have revived long-discredited claims linking vaccines and Tylenol to autism, despite overwhelming scientific consensus to the contrary. Peer-reviewed studies, including a 2025 Johns Hopkins meta-analysis and NIH reviews, consistently find no evidence for such links. The newly formed Independent Autism Coordinating Committee aims to uphold evidence-based public health messaging, while researchers emphasize understanding autism as neurological variation rather than deficit.
Several states are adjusting Medicaid policies for autism support services to strengthen oversight, while federal funding allocations face reevaluation. North Carolina has revised rules for out-of-state providers and telehealth delivery of Applied Behavior Analysis (ABA) supports, following $505 million in state and federal spending on these services. Minnesota is implementing reforms after an audit identified gaps in fraud monitoring. The Autism CARES Act reauthorization allocated $2 billion for 2025-2030, though NIH autism research funding faces potential adjustments.
A retracted clinical trial on leucovorin (folinic acid) has prompted reevaluation of evidence for pharmaceutical approaches to support autistic individuals, particularly regarding social communication differences. While the FDA has approved leucovorin only for cerebral folate deficiency—a rare co-occurring condition—this development highlights ongoing discussions about how best to support diverse neurological needs. Recent reviews suggest most medication research remains in early stages, with few approaches demonstrating consistent benefits for autistic individuals' core experiences.
Autism researchers have formed the Independent Autism Coordinating Committee to safeguard evidence-based science amid political shifts in official health communications. Recent studies with cohorts exceeding 100,000 participants reaffirm no causal links between vaccines, prenatal acetaminophen use, and autism, while the field moves toward neurodiversity-affirming frameworks.
The federal government has expanded autism funding in 2026, including a $1.95 billion reauthorization of the Autism CARES Act, while states like North Carolina and Minnesota introduce new regulations for Medicaid-funded autism services to address billing concerns.
The FDA has explicitly stated that leucovorin, a folate supplement, is not approved for autism treatment despite growing unapproved use. This highlights ongoing challenges in developing drugs for autism's core aspects, with current medications only addressing associated behaviors like irritability.
Leading autism researchers have formed an independent committee to counter misinformation promoted by political figures, reaffirming robust evidence that vaccines and Tylenol do not cause autism. The group also challenges outdated psychological models while emphasizing neurodiversity and practical implications for families.
